Reports by Industry
Reports by Company
- Company Analysis(173)
- Company Profile(60)
Promising Outlook - US Cancer Vaccine Market
Format : 
Adobe Reader (PDF) Upto 24 hour delivery
Publish Date : Aug, 2018| No. of Pages : 150
Please make your selection :
Electronic Access - Single User License
US$ 1400.00
CD-ROM Mail Delivery
US$ 1600.00
Hard Copy Mail Delivery
US$ 1600.00
Electronic Access - Multi-User License
US$ 2000.00
1. Analyst View
2. Research Methodology
3. Cancer Statistics by Demographics
3.1 Incidences and Mortality
3.2 Leading States by Incidences
3.3 Leading Cancers by Incidences
3.3.1 Male Cancer Incidences
3.3.2 Female Cancer Incidences
3.3.3 Children Cancer Incidences
4. Market Dynamics
4.1 Drivers
4.1.1 Rising Cancer Incidences
4.1.2 Ability to Reduce Healthcare Expenditure
4.1.3 Rising Awareness
4.1.4 Patient Assistance Programs
4.1.5 Government Initiatives
4.1.6 Strong Pipeline
4.1.7 Technological Advancements
4.2 Restraints
4.2.1 High Cost of Cancer Vaccines
4.2.2 Side-Effects of Cancer Vaccines
4.2.3 Vaccine Supply Shortages
4.2.4 Insurance Issues Related to Cancer Vaccination
4.3 Opportunities
4.3.1 Therapeutic Cancer Vaccines
4.3.2 Adjuvant Cancer Vaccines
5. Cancer Vaccines Market Outlook
5.1 Key Product Analysis
5.1.1 Provenge
5.1.1.1 Market Analysis
5.1.2 T-Vec/Imlygic
5.1.2.1 Market Analysis
5.1.3 HPV Vaccine
5.1.3.1 Gardasil
5.1.3.1.1 Market Analysis
5.1.3.2 Cervarix
5.1.3.2.1 Market Analysis
5.1.4 HBV Vaccines
5.1.4.1 Engerix-B & Twinrix
5.1.4.1.1 Market Analysis
5.1.4.2 Recombivax HB
5.1.4.2.1 Market Analysis
5.1.4.3 Pediarix/ Infanrix
5.1.4.3.1 Market Analysis
6. Cancer Vaccines Market by Cancer Type
7. Cancer Vaccine Market by Application
8. Potential Cancer Vaccine Candidates: An Opportunity Assessment
8.1 Prophylactic Vaccine
8.2 Therapeutic Vaccine
8.2.1 Prostate Cancer
8.2.2 Breast Cancer
8.2.3 Lung Cancer
8.2.4 Colorectal Cancer
9. US Patent Analysis
9.1 Patents by Year
9.2 Patents by Category
9.2.1 Utility Patents
9.2.2 Design Patents
9.2.3 Plant Patents
9.3 Patents by Company
9.4 Patents by Assignee Type
9.4.1 By Assignee Name
9.4.2 By Assignee State
10. Regulatory Environment
10.1 Vaccine Approval Process
10.2 FDA Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines
10.2.1 Considerations for both Early and Late Phase Clinical Trials
10.2.1.1 Patient Population
10.2.1.2 Monitoring the Immune Response
10.2.1.3 Biomarkers as Evidence of Efficacy
10.2.1.4 Adjuvants Used to Stimulate Immune Response
10.2.1.5 Multi-antigen Vaccines
10.2.1.6 Disease Progression/Recurrence Immediately or Shortly after the Initial Administration of Cancer Vaccines
10.2.1.7 Concomitant and Subsequent Therapies
10.2.2 Considerations for Early Phase Clinical Trials
10.2.2.1 Starting Dose and Dosing Schedule
10.2.2.2 Booster and Maintenance Therapy
10.2.2.3 Dose Escalation
10.2.2.4 Single-arm versus Randomized Phase-2 Trials in Early Development
10.2.3 Considerations for Late Phase Clinical Trials
10.2.3.1 Safety Profile from Early Phase Clinical Trials
10.2.3.2 Endpoints
10.2.3.3 Statistical Issues
10.2.3.4 Control Issues
10.2.3.5 Delayed Vaccine Effect
10.2.3.6 Autologous Vaccine Trials
10.2.3.7 Accelerated Approval Regulations
11. Competitive Landscape
12. Company Profiles
12.1 Merck & Co., Inc.
12.2 GlaxoSmithKline plc.
12.3 Dendreon Pharmaceuticals LLC
12.4 Amgen Inc.
Not able to find data you are looking for? Ask our Research Analyst.
media citation
- testtest
19 Jan, 2024 - Yourstory.com News @ Foodtech startup Swiggy launches Health Hub in Chennai
23 Mar, 2021 - Yourstory.com News @ Zomato forays into dietary supplements, makes its own 'made in India' brand
16 Mar, 2021 - View more
get in touch
Copyright © 2018, RNCOS, 2002-2018
About Us
Terms & Policy
Contact